单独使用他克莫司软膏治疗小儿白癜风的安全性和有效性:系统评价和荟萃分析。

Biomedicine hub Pub Date : 2024-12-30 eCollection Date: 2025-01-01 DOI:10.1159/000543311
Alshaymaa Abdulrahman Alshaikh, Joud Abdulrahman Alshaikh, Hind Alatawi
{"title":"单独使用他克莫司软膏治疗小儿白癜风的安全性和有效性:系统评价和荟萃分析。","authors":"Alshaymaa Abdulrahman Alshaikh, Joud Abdulrahman Alshaikh, Hind Alatawi","doi":"10.1159/000543311","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vitiligo, a skin disorder affecting melanocytes, poses treatment challenges. There is a need to investigate the role of tacrolimus in pediatric cases for its efficacy and safety. The present study aimed to assess the safety and efficacy of tacrolimus ointment in treating pediatric vitiligo patients.</p><p><strong>Methods: </strong>A review study was conducted, and a literature search was done on 2 August 2023, by using the words \"vitiligo\" and \"tacrolimus\" through five databases including PubMed. We found 8 studies from 930 records.</p><p><strong>Results: </strong>The rates of excellent, moderate, mild, minimal improvement, and no response were 29% (95% CI: 16-47), 26% (95% CI: 19-35), 28% (95% CI: 20-37), 19% (95% CI: 12-29), and 8% (95% CI: 2-25). No systemic side effects were reported. The overall prevalence of local side effects was 14% (95% CI: 7-24). Burning sensation prevalence was 11% (95% CI: 7-18), while pruritus prevalence was 9% (95% CI: 2-33). Study limitations encompassed varied vitiligo sites, patient demographics, and follow-up durations, lacked comparative treatment data, and necessitated further research on combined therapies, especially in pediatric cases.</p><p><strong>Conclusion: </strong>Tacrolimus showed good efficacy regarding the re-pigmentation improvement in pediatric vitiligo patients. Furthermore, no systemic side effects were reported and local side effects were minimal mainly in the form of a burning sensation and pruritus.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"10 1","pages":"33-43"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793912/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safety and Efficacy of Tacrolimus Ointment Alone in the Treatment of Pediatric Vitiligo: A Systematic Review and Meta-Analysis.\",\"authors\":\"Alshaymaa Abdulrahman Alshaikh, Joud Abdulrahman Alshaikh, Hind Alatawi\",\"doi\":\"10.1159/000543311\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Vitiligo, a skin disorder affecting melanocytes, poses treatment challenges. There is a need to investigate the role of tacrolimus in pediatric cases for its efficacy and safety. The present study aimed to assess the safety and efficacy of tacrolimus ointment in treating pediatric vitiligo patients.</p><p><strong>Methods: </strong>A review study was conducted, and a literature search was done on 2 August 2023, by using the words \\\"vitiligo\\\" and \\\"tacrolimus\\\" through five databases including PubMed. We found 8 studies from 930 records.</p><p><strong>Results: </strong>The rates of excellent, moderate, mild, minimal improvement, and no response were 29% (95% CI: 16-47), 26% (95% CI: 19-35), 28% (95% CI: 20-37), 19% (95% CI: 12-29), and 8% (95% CI: 2-25). No systemic side effects were reported. The overall prevalence of local side effects was 14% (95% CI: 7-24). Burning sensation prevalence was 11% (95% CI: 7-18), while pruritus prevalence was 9% (95% CI: 2-33). Study limitations encompassed varied vitiligo sites, patient demographics, and follow-up durations, lacked comparative treatment data, and necessitated further research on combined therapies, especially in pediatric cases.</p><p><strong>Conclusion: </strong>Tacrolimus showed good efficacy regarding the re-pigmentation improvement in pediatric vitiligo patients. Furthermore, no systemic side effects were reported and local side effects were minimal mainly in the form of a burning sensation and pruritus.</p>\",\"PeriodicalId\":101351,\"journal\":{\"name\":\"Biomedicine hub\",\"volume\":\"10 1\",\"pages\":\"33-43\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793912/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedicine hub\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000543311\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine hub","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000543311","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

白癜风是一种影响黑色素细胞的皮肤病,对治疗提出了挑战。有必要调查他克莫司在儿科病例中的作用,以确定其有效性和安全性。本研究旨在评价他克莫司软膏治疗小儿白癜风患者的安全性和有效性。方法:于2023年8月2日进行回顾性研究,检索PubMed等5个数据库,检索词为“白癜风”和“他克莫司”。我们从930条记录中找到了8项研究。结果:极、中度、轻度、轻微改善和无反应率分别为29% (95% CI: 16-47)、26% (95% CI: 19-35)、28% (95% CI: 20-37)、19% (95% CI: 12-29)和8% (95% CI: 2-25)。没有系统性副作用的报道。局部副作用的总体发生率为14% (95% CI: 7-24)。烧灼感患病率为11% (95% CI: 7-18),瘙痒患病率为9% (95% CI: 2-33)。研究的局限性包括不同的白癜风部位、患者人口统计学和随访时间,缺乏比较治疗数据,需要进一步研究联合治疗,特别是在儿科病例中。结论:他克莫司对改善小儿白癜风患者的再色素沉着有较好的疗效。此外,没有系统性副作用的报道,局部副作用最小,主要表现为烧灼感和瘙痒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safety and Efficacy of Tacrolimus Ointment Alone in the Treatment of Pediatric Vitiligo: A Systematic Review and Meta-Analysis.

Introduction: Vitiligo, a skin disorder affecting melanocytes, poses treatment challenges. There is a need to investigate the role of tacrolimus in pediatric cases for its efficacy and safety. The present study aimed to assess the safety and efficacy of tacrolimus ointment in treating pediatric vitiligo patients.

Methods: A review study was conducted, and a literature search was done on 2 August 2023, by using the words "vitiligo" and "tacrolimus" through five databases including PubMed. We found 8 studies from 930 records.

Results: The rates of excellent, moderate, mild, minimal improvement, and no response were 29% (95% CI: 16-47), 26% (95% CI: 19-35), 28% (95% CI: 20-37), 19% (95% CI: 12-29), and 8% (95% CI: 2-25). No systemic side effects were reported. The overall prevalence of local side effects was 14% (95% CI: 7-24). Burning sensation prevalence was 11% (95% CI: 7-18), while pruritus prevalence was 9% (95% CI: 2-33). Study limitations encompassed varied vitiligo sites, patient demographics, and follow-up durations, lacked comparative treatment data, and necessitated further research on combined therapies, especially in pediatric cases.

Conclusion: Tacrolimus showed good efficacy regarding the re-pigmentation improvement in pediatric vitiligo patients. Furthermore, no systemic side effects were reported and local side effects were minimal mainly in the form of a burning sensation and pruritus.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信